MAM
McCann Worldgroup appoints Sanjeev Chopra as SVP & head, McCann Health – Delhi
MUMBAI: Sanjeev Chopra has joined McCann Health as senior vice president and head McCann Health – Delhi. He has over 25 years of experience in healthcare advertising, marketing & sales. He moves from Publicis Health.
Chopra has earlier worked with companies like Wockhardt, Crosslands, a division of Ranbaxy Laboratories Ltd., McCann Health, Publicis India, Aspire Cerebro. He has worked on clients like Sanofi, Sanofi Pasteur, Abbott, Sun Pharma, Pfizer, Lupin, Zydus, Novartis, Astra Zeneca, Novo Nordisk, Draeger, J&J, Dr. Reddy’s, GSK, Glenmark, Wockhardt Pharma, Perkin Elmer, Pregna, MSD, Cipla, Lupin, Narottam Seksaria Foundation (Anti-tobacco), BMC Mumbai, Wockhardt Hospitals, Sion Hospital, KEM Hospital & Baljiwan Pharma, etc.
Commenting on Chopra’s appointment, McCann Asia Pacific Chairman, and McCann Worldgroup India CEO & CCO Prasoon Joshi said, “I am extremely happy to have Sanjeev come on aboard in a key role. He is passionate about the business and I am sure this will further strengthen our McCann Health operations in Delhi with his vast experience in healthcare space.”
On joining the agency, Chopra said, “I am thrilled to join back McCann Health, a place from where I had started my agency journey. McCann Health has all that makes it a leader agency – enjoys amazing confidence of well-known clients in health & nutrition domain, has extraordinary talent and exhibits ever-growing hunger to win reputed awards. Healthcare communication industry is currently experiencing exciting times – clients are implementing ideas generated by out-of-box thinking and technology is playing a role like never before. Indeed, this is the best time for me to join the best agency.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
